Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Update

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 52,120,000 shares, a growth of 21.3% from the December 15th total of 42,970,000 shares. Based on an average daily trading volume, of 16,430,000 shares, the short-interest ratio is currently 3.2 days. Approximately 29.4% of the shares of the stock are short sold.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 7,500 shares of the firm's stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $22.20, for a total transaction of $166,500.00. Following the sale, the insider now owns 193,980 shares in the company, valued at $4,306,356. This trade represents a 3.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Soleil Boughton sold 268,932 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the transaction, the insider now owns 169,803 shares of the company's stock, valued at $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,080,208 shares of company stock valued at $29,106,823. Company insiders own 17.71% of the company's stock.

Institutional Trading of Hims & Hers Health

Several large investors have recently bought and sold shares of the company. Raleigh Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares during the period. GAMMA Investing LLC raised its holdings in Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company's stock worth $54,000 after purchasing an additional 2,152 shares in the last quarter. Quest Partners LLC lifted its position in Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company's stock valued at $81,000 after buying an additional 807 shares during the period. CWM LLC lifted its position in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after buying an additional 1,054 shares during the period. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 115.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company's stock valued at $110,000 after buying an additional 2,442 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Price Performance

NYSE:HIMS traded down $0.14 during trading hours on Friday, hitting $27.80. The company had a trading volume of 18,842,443 shares, compared to its average volume of 10,492,087. The stock has a 50-day moving average price of $27.60 and a 200 day moving average price of $21.80. The company has a market capitalization of $6.07 billion, a PE ratio of 63.19 and a beta of 1.31. Hims & Hers Health has a 52 week low of $8.14 and a 52 week high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the previous year, the firm posted ($0.04) EPS. The company's revenue for the quarter was up 77.1% compared to the same quarter last year. Analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HIMS. Citigroup lowered Hims & Hers Health from a "neutral" rating to a "sell" rating and upped their target price for the stock from $24.00 to $25.00 in a research note on Friday, January 10th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research note on Wednesday, November 6th. BTIG Research started coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 target price on the stock. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, December 17th. They set an "overweight" rating and a $42.00 price target for the company. Finally, TD Cowen reiterated a "buy" rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.